The world’s first monoclonal antibody-directed drug for the treatment of primary hepatocellular liver cancer, and the first antibody-based drug with independent intellectual property rights in China, methotrexate injection (Licartin), was officially applied to clinical practice today in the Interventional Department of Shanghai Tenth People’s Hospital affiliated to Tongji University in our city. Liver cancer is one of the common malignant tumors. For a long time, surgical resection has become the main effective method for treating liver cancer because there is no specialized treatment drug. However, the surgical resection rate of hepatocellular carcinoma is less than 15% at this stage, and high recurrence and metastasis after surgery are still a worldwide problem. For patients with hepatocellular carcinoma who cannot undergo surgery, interventional treatment has achieved better efficacy, and the medium and long-term survival rate is low, with less than 30% of patients with hepatocellular carcinoma treated with interventional treatment surviving for more than 3 years. Methotrexamab injection, as a national Class I new drug for the treatment of primary hepatocellular liver cancer, creatively uses HAb18 F(ab’)2 monoclonal antibody fragment as the guiding carrier, and takes advantage of its high affinity for liver cancer cells to bring the drug to the liver cancer site, thus specifically killing tumor cells without injuring normal tissues. After using this product, there is no accumulation of the drug in other organs of the body, which is the first “liver cancer-oriented drug” in China. The clinical trial results of the drug show that the clinical control rate is 80% in one treatment cycle and 86% in two treatment cycles; compared with traditional surgery, the injection of methotrexate only requires a rice-sized incision in the patient’s femoral artery, which is almost painless; the side effects caused by the interventional injection of methotrexate, such as vomiting and hair loss, are smaller. Following its first application in the Department of Interventional Medicine of the Tenth People’s Hospital of Tongji University today, this drug has the potential to promote the leapfrog development of comprehensive treatment technology for hepatocellular carcinoma, resulting in a significant improvement in the long-term survival rate of patients with hepatocellular carcinoma for more than 3 years, and may even lead to a complete non-surgical clinical cure for primary hepatocellular carcinoma.